Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial

(2017) J. L. Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of induction with cybord in newly diagnosed multiple myeloma

(2017) C. B. Reeder et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib, pegylated-lyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous stem cell transplant (ASCT) followed by lenalidomide and prednisone (LP) as consolidation and lenalidomide alone as maintenance

(2017) A. P. Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

(2008) F. Zhan et al.   BLOOD

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

(2008) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY

A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy

(2008) P L Bergsagel   LEUKEMIA